AstraZeneca’s Imfinzi shows promise in treating aggressive lung cancer

April 5 (Reuters) – Drugmaker AstraZeneca said on Friday its blockbuster cancer drug Imfinzi showed “significant and clinically meaningful” improvement in the primary goals of a late-stage trial designed for an aggressive type of lung cancer.

Imfinzi demonstrated improvement in the dual primary goals of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy, the company said in a statement.

(Reporting by Eva Mathews in Bengaluru; Editing by Rashmi Aich)

(c) Copyright Thomson Reuters 2024. Click For Restrictions – https://agency.reuters.com/en/copyright.html